Business Context and Reporting Period
This Form 8-K was filed by Biorestorative Therapies, Inc. on March 6, 2014. The report addresses Item 5.02 regarding compensatory arrangements for the Chief Executive Officer for the fiscal year ended December 31, 2013.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to executive compensation adjustments:
- CEO Salary (2013): Agreed at $360,000.
- Original Entitlement: $600,000 annual salary.
- CEO Bonus (2013): $0 (waived).
- Original Bonus Entitlement: $300,000.
Material Changes
The material change reported is a significant reduction in the Chief Executive Officer's total compensation for the 2013 fiscal year. Mr. Mark Weinreb agreed to accept a salary of $360,000, representing a $240,000 reduction from his entitled salary, and waived a $300,000 bonus entirely.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks and contingencies beyond the executive compensation agreement.
Investor Verification Checklist
- Verify the total cash savings realized by the company from the CEO compensation reduction ($540,000).
- Confirm if this compensation adjustment was part of a broader cost-cutting initiative or a specific agreement with the Board.
- Review the company's most recent 10-K or 10-Q to assess overall liquidity and cash burn rates in the context of this salary reduction.